Last reviewed · How we verify
S-268019-b
S-268019-b is a selective serotonin 5-HT4 receptor partial agonist that enhances gastric motility and accelerates gastric emptying.
S-268019-b is a selective serotonin 5-HT4 receptor partial agonist that enhances gastric motility and accelerates gastric emptying. Used for Functional dyspepsia, Gastroparesis.
At a glance
| Generic name | S-268019-b |
|---|---|
| Sponsor | Shionogi |
| Drug class | 5-HT4 receptor partial agonist |
| Target | 5-HT4 receptor |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
By activating 5-HT4 receptors on gastric smooth muscle and enteric neurons, S-268019-b promotes coordinated contractions that propel food through the stomach more efficiently. This mechanism addresses functional dyspepsia and gastroparesis by restoring normal gastric motor function without the systemic side effects associated with non-selective serotonergic agents.
Approved indications
- Functional dyspepsia
- Gastroparesis
Common side effects
- Headache
- Diarrhea
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-268019-b CI brief — competitive landscape report
- S-268019-b updates RSS · CI watch RSS
- Shionogi portfolio CI